Clinical Trial Update: Lorlatinib Combinations in Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring lorlatinib combinations in lung cancer with ALK translocations and related resistant/metabolic alterations; status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Lymphoma Kinase Gene Translocation
• Cancer
• Lung Cancer
• Met Amplification
• Non-small Cell Lung Cancer
• Resistant Cancer
• Ros1 Rearrangement

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1, Phase 2 | Status: UNKNOWN